Dr Jonathan Kwok
Dr Jonathan Kwok is a British-Hong Kong clinician scientist, entrepreneur, and CEO and co-founder of Infinitopes, the Oxford-based precision cancer vaccine company spun out of Cancer Research UK and the University of Oxford. His career has been defined by a commitment to translating foundational immunology research into clinical therapies for patients with the most pressing unmet oncological needs.
Kwok brings over two decades of multidisciplinary experience across oncology, vaccinology, clinical trials, strategy consulting, and investment banking. He is a CRUK cancer vaccines fellow at Oxford University, where his clinical research has focused on the intersection of tumour immunology and vaccine platform design. Before founding Infinitopes, he built expertise spanning both the scientific and commercial dimensions of drug development — an unusual combination that has been critical in steering a complex biotech from academic research to Phase I clinical trials.
In 2021, Kwok co-founded Infinitopes alongside Lian Ni Lee and Dr Senthil Chinnakannan, drawing on CRUK-funded research from the laboratories of Professor Paul Klenerman and Associate Professor Nicola Ternette at Oxford. As CEO, he assembled an in-house team covering antigen discovery, T-cell immunology, vaccinology, biomanufacturing, and clinical operations, and secured the company's MHRA Innovative Licensing and Access Pathway innovation passport — the first of its kind for a cancer vaccine — alongside two maximum-size Innovate UK awards.
Infinitopes' lead candidate, ITOP1, entered a Phase I/IIa clinical trial across NHS university cancer centres in 2026 — the VISTA study. The company has raised $35 million in total seed financing, with the second close co-led by Octopus Ventures and Amplify Bio. Kwok describes his mission as developing accessible, high-efficiency vaccines that prevent the cancer metastases responsible for 70 to 90 percent of cancer deaths — and doing so in a way that is scalable, not personalised to each individual patient.
